| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Channa N Jayasena, Chioma Izzi-Engbeaya, Shakunthala Narayanaswamy, Manish Modi, Holly Clarke, Gurjinder M K Nijher, Karim Meeran, Waljit S Dhill. Associations of coefficient of variation of serum GH with previous radiotherapy, hypopituitarism and cardiac disease in patients with treated acromegaly. Clinical endocrinology. vol 82. issue 6. 2016-03-03. PMID:25439593. |
associations of coefficient of variation of serum gh with previous radiotherapy, hypopituitarism and cardiac disease in patients with treated acromegaly. |
2016-03-03 |
2023-08-13 |
Not clear |
| Channa N Jayasena, Chioma Izzi-Engbeaya, Shakunthala Narayanaswamy, Manish Modi, Holly Clarke, Gurjinder M K Nijher, Karim Meeran, Waljit S Dhill. Associations of coefficient of variation of serum GH with previous radiotherapy, hypopituitarism and cardiac disease in patients with treated acromegaly. Clinical endocrinology. vol 82. issue 6. 2016-03-03. PMID:25439593. |
the coefficient of variation of serum gh (ghcv) during oral glucose tolerance test (ogtt) quantifies the variation of gh secretion in patients with acromegaly, but has not been reported previously. |
2016-03-03 |
2023-08-13 |
Not clear |
| Georgia Ntali, Niki Karavitak. Recent advances in the management of acromegaly. F1000Research. vol 4. 2016-02-26. PMID:26918140. |
acromegaly is a rare condition of gh excess associated with significant morbidities (e.g. |
2016-02-26 |
2023-08-13 |
Not clear |
| Taiba Zornitzki, Hadara Rubinfeld, Lyudmila Lysyy, Tal Schiller, Véronique Raverot, Ilan Shimon, Hilla Knoble. pNET co-secreting GHRH and calcitonin: ex vivo hormonal studies in human pituitary cells. Endocrinology, diabetes & metabolism case reports. vol 2016. 2016-02-23. PMID:26904199. |
following surgical resection of the pancreatic tumor, igf1, gh and calcitonin normalized, and the clinical features of acromegaly improved. |
2016-02-23 |
2023-08-13 |
human |
| Taiba Zornitzki, Hadara Rubinfeld, Lyudmila Lysyy, Tal Schiller, Véronique Raverot, Ilan Shimon, Hilla Knoble. pNET co-secreting GHRH and calcitonin: ex vivo hormonal studies in human pituitary cells. Endocrinology, diabetes & metabolism case reports. vol 2016. 2016-02-23. PMID:26904199. |
the ability of the pnet-derived medium to stimulate in vitro gh release from a human pituitary-cell culture, combined with the clinical and hormonal remission following tumor resection, confirmed the ectopic source of acromegaly in this patient. |
2016-02-23 |
2023-08-13 |
human |
| A Benfante, A Ciresi, M Bellia, F Cannizzaro, V Bellia, C Giordano, N Scichilon. Early lung function abnormalities in acromegaly. Lung. vol 193. issue 3. 2016-02-11. PMID:25757541. |
acromegaly is an insidious disorder caused by a pituitary growth hormone (gh)-secreting adenoma resulting in high circulating levels of gh and insulin-like growth factor i (igf-i). |
2016-02-11 |
2023-08-13 |
Not clear |
| C Gérard, H Jedidi, P Petrossians, F Krzesinski, A Daly, A Becker. [Old phenotype and new genotypes. Pituitary adenomas]. Revue medicale de Liege. vol 70. issue 11. 2016-02-01. PMID:26738269. |
gigantism and acromegaly, usually caused by a pituitary adenoma linked inappropriate secretion of growth hormone (gh), are generally considered as very rare diseases, even if, according to some authors, their cumulative prevalence is about 1/5000. |
2016-02-01 |
2023-08-13 |
Not clear |
| David Petroff, Anke Tönjes, Martin Grussendorf, Michael Droste, Christina Dimopoulou, Günter Stalla, Cornelia Jaursch-Hancke, Manuel Mai, Jochen Schopohl, Christof Schöf. The Incidence of Cancer Among Acromegaly Patients: Results From the German Acromegaly Registry. The Journal of clinical endocrinology and metabolism. vol 100. issue 10. 2016-01-13. PMID:26244491. |
acromegaly is a rare disease characterized by high serum levels of gh and igf-1. |
2016-01-13 |
2023-08-13 |
Not clear |
| S E Franck, A J van der Lely, P J D Delhanty, J O L Jørgensen, S J C M M Negger. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. European journal of endocrinology. vol 173. issue 5. 2016-01-12. PMID:26243033. |
pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the gh receptor deletion of exon 3. |
2016-01-12 |
2023-08-13 |
Not clear |
| S E Franck, A J van der Lely, P J D Delhanty, J O L Jørgensen, S J C M M Negger. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. European journal of endocrinology. vol 173. issue 5. 2016-01-12. PMID:26243033. |
doses of the gh receptor (ghr) antagonist pegvisomant (pegv) that normalize insulin-like growth factor 1 (igf1) levels vary widely among acromegaly patients. |
2016-01-12 |
2023-08-13 |
Not clear |
| Cristina Capatina, John A H Was. 60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly. The Journal of endocrinology. vol 226. issue 2. 2015-12-29. PMID:26136383. |
acromegaly (acm) is a chronic, progressive disorder caused by the persistent hypersecretion of gh, in the vast majority of cases secreted by a pituitary adenoma. |
2015-12-29 |
2023-08-13 |
Not clear |
| Ali Erdem Yildirim, Mert Sahinoglu, Denizhan Divanlioglu, Fatih Alagoz, Ahmet Gurhan Gurcay, Ergun Daglioglu, Hilmi Onder Okay, Ahmed Deniz Bele. Endoscopic endonasal transsphenoidal treatment for acromegaly: 2010 consensus criteria for remission and predictors of outcomes. Turkish neurosurgery. vol 24. issue 6. 2015-12-22. PMID:25448208. |
acromegaly is a chronic disorder characterized by enhanced growth hormone (gh) secretion and elevated insulin-like growth factor-i (igf-i) levels, usually caused by pituitary adenomas. |
2015-12-22 |
2023-08-13 |
Not clear |
| Riia K Junnila, Christian J Strasburger, Martin Bidlingmaie. Pitfalls of insulin-like growth factor-i and growth hormone assays. Endocrinology and metabolism clinics of North America. vol 44. issue 1. 2015-12-22. PMID:25732639. |
accurate measurement of growth hormone (gh) and insulin-like growth factor-i (igf-i) are the key to correct diagnosis of acromegaly and gh deficiency. |
2015-12-22 |
2023-08-13 |
Not clear |
| Ido Wolf, Shiri Shahmoon, Michal Ben Ami, Yael Levy-Shraga, Kineret Mazor-Aronovitch, Orit Pinhas-Hamiel, Yonatan Yeshayahu, Rina Hemi, Hannah Kanety, Tami Rubinek, Dalit Modan-Mose. Association between decreased klotho blood levels and organic growth hormone deficiency in children with growth impairment. PloS one. vol 9. issue 9. 2015-12-16. PMID:25198618. |
recent data also indicated an association between klotho levels and growth hormone (gh) levels in acromegaly. |
2015-12-16 |
2023-08-13 |
mouse |
| Ana Valea, Cristina Ghervan, Mara Carsote, Andra Morar, Iulia Iacob, Florica Tomesc, Dan Dumitru Pop, Carmen Georgesc. Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly. Clujul medical (1957). vol 88. issue 3. 2015-11-26. PMID:26609262. |
effects of combination therapy: somatostatin analogues and dopamine agonists on gh and igf1 levels in acromegaly. |
2015-11-26 |
2023-08-13 |
Not clear |
| Ana Valea, Cristina Ghervan, Mara Carsote, Andra Morar, Iulia Iacob, Florica Tomesc, Dan Dumitru Pop, Carmen Georgesc. Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly. Clujul medical (1957). vol 88. issue 3. 2015-11-26. PMID:26609262. |
acromegaly is a complex endocrine disorder caused by excessive secretion of gh, secondary to a gh secreting pituitary adenoma or a mixed pituitary adenoma secreting gh and prl. |
2015-11-26 |
2023-08-13 |
Not clear |
| Carlos M Reyes-Vidal, Hamed Mojahed, Wei Shen, Zhezhen Jin, Fernando Arias-Mendoza, Jean Carlos Fernandez, Dympna Gallagher, Jeffrey N Bruce, Kalmon D Post, Pamela U Fred. Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment. The Journal of clinical endocrinology and metabolism. vol 100. issue 8. 2015-11-17. PMID:26037515. |
however, when in excess in acromegaly, the lipolytic and insulin antagonistic effects of gh may alter adipose tissue (at) deposition. |
2015-11-17 |
2023-08-13 |
Not clear |
| Jörgen Isgaard, Michele Arcopinto, Kristjan Karason, Antonio Cittadin. GH and the cardiovascular system: an update on a topic at heart. Endocrine. vol 48. issue 1. 2015-11-11. PMID:24972804. |
physiological effects of gh and underlying mechanisms for interactions between gh and insulin-like growth factor i (igf-i) and the cardiovascular system are covered as well as the cardiac dysfunction caused both by gh excess (acromegaly) and by gh deficiency in adult hypopituitary patients. |
2015-11-11 |
2023-08-13 |
Not clear |
| Jörgen Isgaard, Michele Arcopinto, Kristjan Karason, Antonio Cittadin. GH and the cardiovascular system: an update on a topic at heart. Endocrine. vol 48. issue 1. 2015-11-11. PMID:24972804. |
in both acromegaly and adult gh deficiency, there is also increased cardiovascular morbidity and mortality possibly linked to aberrations in gh status. |
2015-11-11 |
2023-08-13 |
Not clear |
| Pedro Weslley Rosario, Maria Regina Calsolar. Safety and specificity of the growth hormone suppression test in patients with diabetes. Endocrine. vol 48. issue 1. 2015-11-10. PMID:24833548. |
the purpose of this study was to evaluate the safety of the oral glucose tolerance test (ogtt) and its capacity to suppress growth hormone (gh) in diabetic patients without acromegaly. |
2015-11-10 |
2023-08-13 |
human |